» Articles » PMID: 20406782

Inflammatory Events in Endometrial Adenocarcinoma

Overview
Journal J Endocrinol
Specialty Endocrinology
Date 2010 Apr 22
PMID 20406782
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Endometrial adenocarcinoma is the most common gynaecological malignancy in western countries. Many of the established risk factors for developing endometrial cancer are associated with excess exposure to oestrogen unopposed by progesterone. These include nulliparity, late onset of the menopause, post-menopausal hormone replacement therapy and obesity. However, a number of risk factors also promote inflammation, another feature proposed to influence cancer development. The human cycling endometrium undergoes regular and cyclical episodes of inflammation. Moreover, hormonal and genetic changes that occur early in the development of endometrial adenocarcinoma can exacerbate the local inflammatory environment. Via alterations in the expression of local mediators and immune cell function, these may contribute to the development of endometrial cancer. This review discusses the contribution of inflammation to the initiation and progression of endometrial adenocarcinoma. Manipulation of inflammatory pathways may therefore represent a therapeutic target in endometrial adenocarcinoma.

Citing Articles

Effect of ultrasound-guided transverse abdominal plane block on neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune inflammation index in patients undergoing radical resection of endometrial carcinoma.

Wang C, Fan S, Gu D, Deng J, Ma B, Xie L PLoS One. 2024; 19(12):e0315175.

PMID: 39637188 PMC: 11620674. DOI: 10.1371/journal.pone.0315175.


Why Does Your Uterus Become Malignant? The Impact of the Microbiome on Endometrial Carcinogenesis.

Moranska K, Englert-Golon M, Durda-Masny M, Sajdak S, Grabowska M, Szwed A Life (Basel). 2023; 13(12).

PMID: 38137870 PMC: 10744771. DOI: 10.3390/life13122269.


The crucial value of serum ferritin in assessing high-risk factors and prognosis for patients with endometrial carcinoma.

Liu J, Xuan B, Quan Q, Gong S, Mu X BMC Womens Health. 2023; 23(1):415.

PMID: 37550644 PMC: 10408112. DOI: 10.1186/s12905-023-02575-x.


New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions.

Zhang C, Sheng Y, Sun X, Wang Y Cancer Metastasis Rev. 2023; 42(3):891-925.

PMID: 37368179 PMC: 10584725. DOI: 10.1007/s10555-023-10113-2.


Dietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysis.

Brasky T, Hade E, Cohn D, Newton A, Petruzella S, OConnell K Gynecol Oncol. 2023; 169:137-146.

PMID: 36934308 PMC: 10025515. DOI: 10.1016/j.ygyno.2022.10.015.